RxDoctor Payments Data

Robert Becker, MD

Endocrinology, Diabetes & Metabolism · Camden, NJNPI 1902193311

Payments from drug & device makers

$556in general payments, 2019–2025

Across 40 payments — averaging $13.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$215
  • Abbott$75
  • Sanofi-aventis U.S. LLC$63
  • Lilly USA, LLC$56
  • Boehringer Ingelheim$55
  • Amgen$30
  • plus $63 from 3 others

What the payments were for

  • Food & beverage$556100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$556 in reported general payments places this provider in the 25th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.

See all endocrinology, diabetes & metabolism providers in New Jersey

Medicare billing

Part B allowed, 2024
$98,259
Medicare patients
360
Services billed
1,111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide553$645,461
TrulicityDulaglutide270$354,359
JardianceEmpagliflozin240$277,931
MounjaroTirzepatide167$190,527
RybelsusSemaglutide76$110,500
Humulin R U-500 KwikpenInsulin Regular, Human30$97,985
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog232$94,964
MycapssaOctreotide Acetate13$85,943
FarxigaDapagliflozin Propanediol87$83,901
JanuviaSitagliptin Phosphate84$75,669
Fiasp FlextouchInsulin Aspart (Niacinamide)54$67,456
Humalog Kwikpen U-100Insulin Lispro150$54,160
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog38$51,400
Novolog FlexpenInsulin Aspart112$46,422
TradjentaLinagliptin37$35,630

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Fiasp, Novolog$215$775,657671 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$56$574,441523 claims
Boehringer IngelheimJardiance, Tradjenta$55$313,561277 claims
AstraZenecaFarxiga$28$83,90187 claims
Sanofi-aventis U.S. LLCLantus$63$3,64531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.

Other endocrinology, diabetes & metabolism in Camden

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →